A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins

The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in...

Full description

Saved in:
Bibliographic Details
Published in:Virology (New York, N.Y.) Vol. 345; no. 2; pp. 299 - 304
Main Authors: Bredenbeek, Peter J., Molenkamp, Richard, Spaan, Willy J.M., Deubel, Vincent, Marianneau, Phillippe, Salvato, Maria S., Moshkoff, Dmitry, Zapata, Juan, Tikhonov, Ilia, Patterson, Jean, Carrion, Ricardo, Ticer, Anysha, Brasky, Kathleen, Lukashevich, Igor S.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 20.02.2006
Subjects:
Animals
genetic vectors
glycoproteins
Glycoproteins - genetics
Glycoproteins - metabolism
Guinea Pigs
human health
Humans
Lassa Fever - prevention & control
Lassa mammarenavirus
Lassa virus
Lassa virus - genetics
Lassa virus - immunology
Lassa virus - metabolism
recombinant fusion proteins
Recombinant vaccine
vaccines
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - genetics
Vaccines, Synthetic - metabolism
viral antibodies
viral proteins
Viral Vaccines - administration & dosage
Viral Vaccines - genetics
Viral Vaccines - metabolism
Yellow and Lassa Fevers
yellow fever
Yellow Fever - prevention & control
Yellow Fever Vaccine - administration & dosage
Yellow Fever Vaccine - genetics
Yellow Fever Vaccine - metabolism
Yellow fever virus
Yellow fever virus - immunology
YFV17D vaccine
Africa
YFV17D vaccine
Recombinant vaccine
Yellow and Lassa Fevers
ISSN:0042-6822, 1096-0341
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.
Bibliography:http://www.sciencedirect.com/science/journal/00426822
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0042-6822
1096-0341
DOI:10.1016/j.virol.2005.12.001